

Susan OConnor

From: David Pierce
Sent: Monday, May 1, 2017 3:28 PM
To: Susan OConnor
Subject: FW: Wellspan PRM Analytics License 01_24_2017_v1.docx

Susan,

Can you make sure this is saved on the T drive? Thank you.

David Pierce

Director of Operations, PRM Analytics

Milliman

111 Monument Circle, Suite 601
Indianapolis, IN 46204 USA

+1 317 524 3578 Office

milliman.com

From: Burkholder, Mary [mailto:mburkholder2@wellspan.org]
Sent: Monday, April 10, 2017 4:31 PM
To: David Pierce <david.pierce@milliman.com>; Art Wilmes <art.wilmes@milliman.com>; Mark McCurry <mark@catalystapartners.com>
Cc: Susan OConnor <Susan.OConnor@milliman.com>; Thomas, Kristin C <kthomas6@wellspan.org>
Subject: RE: Wellspan PRM Analytics License 01_24_2017_v1.docx

Hello all,

Below is the email approval from Dr.Chodroff to proceed with our relationship. Meanwhile, we are checking with Legal in regards to the existing BAA as there may be an additional needed due to the fact that Population Health is a different legal entity from WellSpan Health. That is referenced in Dr.Chodroff's email.

Hi Mary,

Please forward this email to our Milliman.

We have successfully completed Milliman's proposed proof of concept project ("Evaluation Period") with satisfactory confidence that PRM Analytics can produce the necessary and accurate reporting for claims and risk analysis. As such, we are committed to fully endorse and proceed with the contractual agreement dated January 31, 2017 that defined this proof of concept project, subject to approval of a Business Associate Agreement.

Regards,

Charles H. Chodroff, MD, MBA, FACP
Senior Vice President, Population Health & Chief Clinical Officer
WellSpan Health
45 Monument Road, Suite 200
York, PA 17403
"Working as one . . . "

Kind Regards,

Mary Burkholder, MBA, Population Health Lead Data Analyst | WellSpan Health | (717)851-3017 | 3421 Concord Road | York, PA 17402

Plant flowers in others' gardens and your life becomes a bouquet

From: David Pierce [<mailto:david.pierce@milliman.com>]

Sent: Thursday, April 06, 2017 5:06 PM

To: Burkholder, Mary <mburkholder2@wellspan.org>; Art Wilmes <art.wilmes@milliman.com>; Mark McCurry <mark@catalystapartners.com>

Cc: Susan OConnor <Susan.OConnor@milliman.com>

Subject: RE: Wellspan PRM Analytics License 01_24_2017_v1.docx

Mary,

I believe the current language covers this scenario. Per exhibit A, additional and existing lines of business enrollment growth are subject to the table. Any lives over the 59K priced will be billed at the rate of \$0.12 PMPM. We will process the commercial claims together to calculate the predictive models but will surface the three commercial populations as separate reports. There would only be additional fees if you exceed the 59K member count we quoted originally.

If you have the Medicare Advantage file in the same extract format as the commercial data, we can work with that. We will require a way to identify the Medicare Advantage lives apart from the Commercial. If the Medicare Advantage data is in its own extract we can handle that as well. Thank you.

David Pierce

Director of Operations, PRM Analytics

Milliman

111 Monument Circle, Suite 601
Indianapolis, IN 46204 USA

+1 317 524 3578 Office

milliman.com

From: Burkholder, Mary [<mailto:mburkholder2@wellspan.org>]

Sent: Thursday, April 06, 2017 3:20 PM

To: David Pierce <david.pierce@milliman.com>; Art Wilmes <art.wilmes@milliman.com>; Mark McCurry <mark@catalystapartners.com>

Cc: Susan OConnor <Susan.OConnor@milliman.com>

Subject: RE: Wellspan PRM Analytics License 01_24_2017_v1.docx

All,

I haven't yet heard back from Dr.Chodroff, but believe that the language will have to be altered in some way to reflect the inclusion of this plan data. You are correct that we won't need any of the Saas quarterly add-ons for these 2 populations, but we will indeed be including their claims and enrollment with our commercial data file. We do want the standard PRM reporting for each as separate plans within the application. Currently, we have <1000 members in the Aetna ACO plan, and about 2800 in our Charity Plan (Healthy Care Card). Does the inclusion of these in our data change the contract pricing?

Regarding Geisinger Medicare Advantage, will you be expecting that data in a separate extract file to load to a Medicare Advantage application?

Kind Regards,

Mary Burkholder, MBA, Population Health Lead Data Analyst | WellSpan Health | (717)851-3017 | 3421 Concord Road | York, PA 17402

Plant flowers in others' gardens and your life becomes a bouquet

From: David Pierce [<mailto:david.pierce@milliman.com>]

Sent: Thursday, April 06, 2017 10:55 AM

To: Burkholder, Mary <mburkholder2@wellspan.org>; Art Wilmes <art.wilmes@milliman.com>; Mark McCurry <mark@catalystapartners.com>

Cc: Susan OConnor <Susan.OConnor@milliman.com>

Subject: RE: Wellspan PRM Analytics License 01_24_2017_v1.docx

Mary,

For the purposes of the covered lives count we only use the assigned lives. The assignable population is available for analysis in the product, but those lives do not count toward the covered lives number. I cannot recall either why those two populations were excluded. I think it was because they are smaller than the minimum lives needed to run the analytics so they would have to be included with the other commercial lives. Please let us know if you have any additional questions. Looking forward to continuing the relationship. Thank you.

David Pierce

Director of Operations, PRM Analytics

Milliman

111 Monument Circle, Suite 601
Indianapolis, IN 46204 USA

+1 317 524 3578 Office

milliman.com

From: Burkholder, Mary [<mailto:mburkholder2@wellspan.org>]

Sent: Wednesday, April 05, 2017 5:35 PM

To: David Pierce <david.pierce@milliman.com>; Art Wilmes <art.wilmes@milliman.com>; Mark McCurry <mark@catalystapartners.com>

Cc: Susan OConnor <Susan.OConnor@milliman.com>

Subject: RE: Wellspan PRM Analytics License 01_24_2017_v1.docx

Sorry, but I have another last minute 't' to cross. Do the total lives include or exclude the MSSP assignable population? I have always assumed assigned or in other words just the covered lives.

Thank you.

----- Original Message -----

Subject: RE: Wellspan PRM Analytics License 01_24_2017_v1.docx

From: "Burkholder, Mary" <mburkholder2@wellspan.org>

Date: Apr 5, 2017, 4:16 PM

To: David Pierce <david.pierce@milliman.com>, Art Wilmes <art.wilmes@milliman.com>, Mark McCurry <mark@catalystapartners.com>

I sent it on its way.

It occurred to me though, why is Aeta Commercial and Healthy Card Charity Plan excluded? We will send those claims combined with the Commercial file containing WellSpan Plus. I honestly don't remember why that note was made, although they are relatively small populations.

Kind Regards,

Mary Burkholder, MBA, Population Health Lead Data Analyst | WellSpan Health | (717)851-3017 | 3421 Concord Road | York, PA 17402

Plant flowers in others' gardens and your life becomes a bouquet

From: David Pierce [<mailto:david.pierce@milliman.com>]

Sent: Wednesday, April 05, 2017 3:22 PM

To: Art Wilmes <art.wilmes@milliman.com>; Burkholder, Mary <mburkholder2@wellspan.org>; Mark McCurry <mark@catalystapartners.com>

Cc: Susan OConnor <Susan.OConnor@milliman.com>

Subject: RE: Wellspan PRM Analytics License 01_24_2017_v1.docx

Mary,

We have the attached signed and executed agreement. Per the provisions in Exhibit A, the trial period can be extended to a full license with written notice that you would like to move forward.

We would need an email or document from Wellspan agreeing to extend the PRM License from the Evaluation Period to a full license subject to the terms in the attached agreement with the contract date of today.

Once we receive that notice, we will confirm receipt and prepare the invoice for contract year 1. Please let us know if this is agreeable to you. Thank you.

David Pierce

Director of Operations, PRM Analytics

Milliman

111 Monument Circle, Suite 601

Indianapolis, IN 46204 USA

+1 317 524 3578 Office

milliman.com

From: Art Wilmes

Sent: Wednesday, April 05, 2017 11:34 AM

To: Burkholder, Mary <mburkholder2@wellspan.org>; David Pierce <david.pierce@milliman.com>; Mark McCurry <mark@catalystapartners.com>

Cc: Susan OConnor <Susan.OConnor@milliman.com>

Subject: RE: Wellspan PRM Analytics License 01_24_2017_v1.docx

WE will revise and send to you. Thank you.

Arthur L Wilmes, FSA, MAAA
Consulting Actuary

Milliman
111 Monument Circle, Suite 601
Indianapolis, IN 46204 USA

+1 317 524 3521 Office
+1 317 439 6719 Mobile

prmanalytics.com



This email and its contents were prepared solely for the internal business use of the Recipient. This email and its contents may not be provided to any third parties without Milliman's prior written consent. Milliman does not intend to benefit any third party recipient of this email and any related work product, even if Milliman consents to the release of its work product to such third party. If you are not the intended recipient, any disclosure, copying, distribution or any action taken or omitted to be taken in reliance on it, is prohibited and may be unlawful. Unless indicated to the contrary: it does not constitute professional advice or opinions upon which reliance may be made by the addressee or any other party, and it should be considered to be a work in progress. Unless otherwise noted in this email or its attachments, this communication does not form a Statement of Actuarial Opinion under American Academy of Actuaries guidelines.

From: Burkholder, Mary [<mailto:mburkholder2@wellspan.org>]
Sent: Wednesday, April 05, 2017 10:28 AM
To: Art Wilmes <art.wilmes@milliman.com>; David Pierce <david.pierce@milliman.com>; Mark McCurry <mark@catalystapartners.com>
Subject: Wellspan PRM Analytics License 01_24_2017_v1.docx

Hello all,
I'm sending this to Dr.Chodroff today for signature but before I do, believe that the effective date needs to be changed. Is this something we can do on our end?

Kind Regards,

Mary Burkholder, MBA, Population Health Lead Data Analyst | WellSpan Health | (717)851-3017 | 3421 Concord Road | York, PA 17402

Plant flowers in others' gardens and your life becomes a bouquet

The information contained in this communication, including all attachments, is legally protected information, confidential or proprietary information, or a trade secret intended solely for the use of the intended recipient or otherwise exempt from disclosure under applicable state and federal law, including, but not limited to, privacy standards imposed pursuant to the federal Health Insurance Portability and Accountability Act of 1996 ("HIPAA"). The information may also be subject to legal privilege. If you are not the intended recipient, you are hereby notified that any use, disclosure, dissemination, distribution, forwarding, or copying of this communication is strictly prohibited. If you have received this communication in error, please notify the sender by reply Fax or e-mail stating the communication was "received in error" and delete or destroy all copies of this communication, including all attachments.

Message string: KqxfH=TU

This communication is intended solely for the addressee and is confidential. If you are not the intended recipient, any disclosure, copying, distribution or any action taken or omitted to be taken in reliance on it, is prohibited and may be unlawful. Unless indicated to the contrary: it does not constitute professional advice or opinions upon which reliance may be made by the addressee or any other party, and it should be considered to be a work in progress.

This communication is intended solely for the addressee and is confidential. If you are not the intended recipient, any disclosure, copying, distribution or any action taken or omitted to be taken in reliance on it, is prohibited and may be unlawful. Unless indicated to the contrary: it does not constitute professional advice or opinions upon which reliance may be made by the addressee or any other party, and it should be considered to be a work in progress.

This communication is intended solely for the addressee and is confidential. If you are not the intended recipient, any disclosure, copying, distribution or any action taken or omitted to be taken in reliance on it, is prohibited and may be unlawful. Unless indicated to the contrary: it does not constitute professional advice or opinions upon which reliance may be made by the addressee or any other party, and it should be considered to be a work in progress.
